3M’s Healthcare Business to Stand on Its Own in April

Solventum will focus on wound care, healthcare IT, oral care, and biopharma filtration.

Omar Ford

February 21, 2024

1 Min Read
Image credit: ERIC LALMAND Getty Images

At a Glance

  • 3M first announced the spinoff in July of 2022.
  • Solventum will be led by Bryan Hanson, Zimmer Biomet's former CEO.
  • Medical device companies are trending more toward spinoffs than huge acquisitions.

3M Healthcare will complete the spin-off of Solventum, its healthcare business, on April 1. The St. Paul, MN-based company filed a form 10 registration statement with the Securities and Exchange Commission.

3M first announced the spinoff in July of 2022. Solventum, which had sales of $8.2 billion in 2023, will focus on wound care, healthcare IT, oral care, and biopharma filtration. 3M said it would retain a 19.9% stake in the business.

The spinoff received its name in November of 2023. 3M said Solventum originates from two words: “solving” and “momentum.” 3M said "Solving" captures the company's dedication to finding breakthrough solutions, while "momentum" symbolizes swifter, nimbler innovation. 3M said the name represents how the independent healthcare company will focus on solving big healthcare challenges and emphasizes the impact it can make on the world.

In August of 2023, Bryan Hanson stepped down from his post at the helm of Zimmer Biomet to serve as CEO of 3M’s healthcare spinoff.

 The Spin is still in

About three years ago a trend emerged in medtech that had larger companies engaging in divestitures and spinoffs. The mega-merger or large-scale mergers began to take a back seat to the spin-offs.

Since then, companies such as GE Healthcare, ZimVie, and Embecta have stepped onto the scene making a strong impact in healthcare.

Related:3M Begins Payments in $6B Defective Earplug Settlement

3M’s spinoff plans came at a time when there were lawsuits from military members who used the company’s allegedly defective earplugs, according to a report from Reuters.

However, there has been one company to somewhat go against the trend - Medtronic.  Earlier this week, the Dublin-based company nixed plans to divest its patient monitoring and interventions businesses.  Medtronic began shopping around the idea of spinning off the businesses in October of 2022.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like